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Introduction: Tiotropium is prescribed for the treatment of chronic obstructive pulmonary 
disease (COPD) and delivered via HandiHaler® (18 µg once daily) or Respimat® Soft Mist™ 
inhaler (5 µg once daily). The recent TIOtropium Safety and Performance In Respimat® 
(TIOSPIR™) study demonstrated that both exhibit similar safety profiles. This analysis provides 
an updated comprehensive safety evaluation of tiotropium® using data from placebo-controlled 
HandiHaler® and Respimat® trials.
Methods: Pooled analysis of adverse event (AE) data from tiotropium HandiHaler® 18 µg and 
Respimat® 5 µg randomized, double-blind, parallel-group, placebo-controlled, clinical trials 
in patients with COPD (treatment duration $4 weeks). Incidence rates, rate ratios (RRs), and 
95% confidence intervals (CIs) were determined for HandiHaler® and Respimat® trials, both 
together and separately.
Results: In the 28 HandiHaler® and 7 Respimat® trials included in this analysis, 11,626 patients 
were treated with placebo and 12,929 with tiotropium, totaling 14,909 (12,469 with HandiHaler®; 
2,440 with Respimat®) patient-years of tiotropium exposure. Mean age was 65 years, and mean 
prebronchodilator forced expiratory volume in 1 second (FEV
1
) was 1.16 L (41% predicted). 
The risk (RR [95% CI]) of AEs (0.90 [0.87, 0.93]) and of serious AEs (SAEs) (0.94 [0.89, 
0.99]) was significantly lower in the tiotropium than in the placebo group (HandiHaler® and 
Respimat® pooled results), and there was a numerically lower risk of fatal AEs (FAEs) (0.90 
[0.79, 1.01]). The risk of cardiac AEs (0.93 [0.85, 1.02]) was numerically lower in the tiotropium 
group. Incidences of typical anticholinergic AEs, but not SAEs, were higher with tiotropium. 
Analyzed separately by inhaler, the risks of AE and SAE in the tiotropium groups remained 
lower than in placebo and similarly for FAEs.
Conclusion: This analysis indicates that tiotropium is associated with lower rates of AEs, 
SAEs, and similar rates of FAEs than placebo when delivered via HandiHaler® or Respimat® 
(overall and separately) in patients with COPD.
Keywords: tiotropium, HandiHaler®, Respimat®
Introduction
Chronic obstructive pulmonary disease (COPD) remains the fourth leading cause of 
death worldwide, although it is both preventable and treatable. It is a major cause of 
morbidity and mortality, and its economic and social burden is projected to increase 
in the coming decades owing to increased risk factors and aging of the population.1 
Although characterized by the expiratory airflow (measured by forced expiratory 
volume in 1 second [FEV
1
]), COPD is associated with an increased incidence of 
comorbidities such as cardiovascular (CV) disease, musculoskeletal impairment, and 
diabetes mellitus, which can affect outcomes and may result in unanticipated adverse 
events (AEs). In addition, patients are often prescribed a number of medications for 
the management of the concomitant diseases, as well as their COPD, and therefore it 
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is important to evaluate the long-term safety and efficacy of 
respiratory treatments.
Tiotropium bromide (SPIRIVA®, Boehringer Ingelheim 
Pharma GmbH & Co KG, Ingelheim am Rhein, Germany) is an 
inhaled, once-daily, long-acting anticholinergic bronchodilator 
indicated for maintenance therapy in patients with COPD,1 
and has been shown to improve lung function, health-related 
quality of life (HRQoL), dyspnea, and exercise tolerance.2–6 
Tiotropium has also been shown to reduce the number and risk 
of exacerbations (including exacerbations leading to hospital-
ization), and to delay the time to first exacerbation.5,7–9
Tiotropium has been available since 2002 as a single-
dose dry-powder formulation delivered via the HandiHaler® 
(Boehringer Ingelheim Pharma GmbH & Co KG) device 
(18 µg),10 and since 2007 as an aqueous solution delivered 
via the multidose Respimat® Soft Mist™ inhaler (SMI) 
(Boehringer Ingelheim Pharma GmbH & Co KG) (5 µg 
once daily).11
Tiotropium HandiHaler® and Respimat® have similar effi-
cacy, safety, and pharmacokinetic profiles,5,12–15 and are well 
established in most countries, with tiotropium HandiHaler® 
being the most prescribed COPD maintenance treatment 
worldwide (with more than 31 million patient-years of use).16
Results from the Understanding Potential Long-term 
Impacts on Function with Tiotropium (UPLIFT®) trial, which 
permitted the concomitant use of long-acting β
2
 agonists 
(LABAs) and theophylline, demonstrated fewer fatal AEs 
(FAEs) with tiotropium HandiHaler® versus placebo and no 
CV safety issues.5,17 In contrast, a post hoc pooled analysis of 
6,096 patients in three 1-year trials and one 6-month trial using 
patient-level data and including vital status data of early discon-
tinued patients showed numerically more deaths with tiotro-
pium Respimat® 5 µg versus placebo, concentrated in patients 
with known cardiac rhythm disorders at study baseline.11,18
Subsequent meta-analyses based on aggregated data and 
reviews of the same Respimat® trial data have suggested 
there might be a significantly increased risk of death with 
tiotropium Respimat® versus placebo19–22; however, other 
meta-analyses, based on individual participant data, did not 
confirm this relationship between tiotropium HandiHaler®23–28 
or Respimat®24 and CV or FAEs versus placebo in patients 
with COPD. Findings from the initial pooled safety analy-
sis of tiotropium Respimat®11,18 drove the initiation of the 
large TIOtropium Safety and Performance In Respimat® 
(TIOSPIR™) trial (n=17,135), in which patients were treated 
over an average period of 2.3 years. The primary endpoint 
of TIOSPIR™ was noninferiority in all-cause mortality 
of Respimat® versus HandiHaler®. The TIOSPIR™ trial 
 demonstrated similar safety (including fatal and CV events) 
and efficacy profiles for tiotropium Respimat® 2.5 and 5 µg, 
and HandiHaler® 18 µg, including patients with cardiac 
arrhythmias at baseline.29
The purpose of this report is to describe the findings of all 
placebo-controlled tiotropium HandiHaler® and tiotropium 
Respimat® trials available to date, as well as to assist health-
care professionals with their decisions regarding prescribing 
tiotropium delivered by either HandiHaler® or Respimat® 
SMI. The safety analysis was determined for HandiHaler® 
and Respimat® trials together as well as separately.
Methods
study population
This pooled safety analysis followed a similar methodology to 
those described by Kesten et al26 and Celli et al24 and describes 
the risk of AEs by calculating a rate ratio (RR). Data from 35 
Phase III and IV tiotropium clinical trials completed as of July 
2012 (listed in Table 1) were included. Of these, 28 trials used 
tiotropium bromide dry powder (delivered via HandiHaler® 
18 µg once daily), and 7 trials used tiotropium bromide solu-
tion (delivered via Respimat® 5 µg once daily). All placebo-
controlled, double-blind, and parallel-group COPD trials of 
$4 weeks’ duration were included in the analysis.
The trials used similar inclusion and exclusion criteria. 
Patients who had a diagnosis of COPD with FEV
1
#70% 
of forced vital capacity, who were aged $40 years and 
had $10 pack-years of smoking history were eligible for inclu-
sion. Exclusion criteria included a diagnosis of asthma, symp-
tomatic prostatic hypertrophy or bladder neck obstruction, 
narrow-angle glaucoma, and known hypersensitivity to trial 
medication or components. Patients with significant disease 
other than COPD that could significantly confound the trial 
results or preclude trial completion were also excluded. Other 
exclusion criteria in earlier trial protocols were heart failure 
resulting in hospitalization in the previous 3 years, cardiac 
arrhythmia requiring drug treatment, or myocardial infarction 
(MI) within the past year. Other than these specific criteria, 
heart failure and ischemic heart disease were not excluded. 
More recent trials used less stringent exclusion criteria, such 
as life-threatening cardiac arrhythmia or arrhythmia requiring a 
change in medication within the last year, heart failure resulting 
in hospitalization in the past year, and/or MI within the preced-
ing 6 months. In study 205.235 (UPLIFT®), moderate to severe 
renally impaired patients were excluded, while in all other 
studies, only severe renally impaired patients were excluded. 
Written informed consent was obtained from all patients, and 
all protocols were approved by an ethics committee.
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Table 1 Clinical trials included in the pooled analysis
NCT trial number  
and/or publication
Boehringer Ingelheim  
trial number
Treatment  
duration (weeks)
Placebo (number  
of patients treated)
Tiotropium (number 
of patients treated)
HandiHaler® 8,343 9,647
Casaburi et al3,a 205.114/117 49 191 279
Casaburi et al3,a 205.115/128 49 180 271
Calverley et al43,a 205.123 6 40 81
Mcnicholas et al44,a 205.124 4 30 65
Brusasco et al2,a  
and Donohue et al45,a
205.130 24 201 209
O’Donnell46,a 205.131 6 100 98
Brusasco et al2,a 205.137 24 199 193
nCT002740147a 205.214 48 510 500
Verkindre et al47,a 205.215 12 54 46
Celli et al48,a 205.218 4 41 40
nCT0027450849,a 205.223 6 130 131
nCT0027452150,a 205.230 25 53 55
nCT001443395,a 205.235 206 3,006 2,986
nCT0015723551,a 205.247 25 117 117
nCT0027405352,a 205.256 38 288 266
nCT0027457353,a 205.257 12 403 1,236
nCT0027726454,a 205.259 48 305 608
nCT002745479,a 205.266 26 915 914
nCT0014432655,a 205.269 12 127 123
nCT0040523655,a 205.270 52 73 69
nCT0027407956,a 205.276 12 195 200
nCT0014419657,a 205.281 12 117 107
nCT0023940858,a 205.282 12 164 147
nCT0023946059,a 205.284 12 96 100
nCT0010682160,a 205.294 8 86 80
nCT0015298461,a 205.301 12 244 228
nCT0052399162 205.365 24 219 238
nCT0052551263 205.368 96 259 260
Respimat® 3,283 3,282
nCT0023947335 205.251 12 91 88
nCT0024043535 205.252 12 90 92
nCT0016884436 205.254 48 319 332
nCT0016883136 205.255 48 334 338
nCT0038708812 205.372 48 1,965 1,952
nCT0012243464 1,205.4 4 55 53
nCT0052899665 1,205.14 24 429 427
Total 11,626 12,929
Note: astudies included in Kesten et al26 meta-analysis.
Abbreviations: BI, Boehringer Ingelheim; NCT, National Clinical Trials (clinicaltrials.gov) identifier number.
All trials permitted the concomitant use of theophyl-
lines, inhaled corticosteroids (ICS), modest daily doses of 
oral corticosteroids (provided the dosing was stable), and 
short-acting β
2
 agonists. Nine out of 35 trials, including the 
long-term safety studies 205.235 (UPLIFT®), 205.266, and 
205.372, also permitted the use of LABAs as prescribed.
adverse event reporting
AEs occurring during the period at risk (defined as the 
period during which the patient received the study drug and 
up to 30 days thereafter) were reported by the investigator. 
Definitions of AEs and serious AEs (SAEs) followed the 
International Conference on Harmonisation guidelines.30 
The cause of death was adjudicated by a Clinical Endpoints 
Committee in studies 205.235 and 205.372 only. Therefore, 
the investigator-reported preferred terms (PTs) were used for 
the pooled analysis rather than the adjudicated terms.
Categorization of aes
All AEs were coded according to the Medical Dictionary 
for Regulatory Activities (MedDRA) version 15.0. The 
dictionary provides individual PTs, and assigns the PTs to 
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so-called system organ classes (SOCs). In some cases, the 
PTs are assigned to more than one SOC, in which case the 
“primary” SOC that was most relevant to the AE has been 
selected. To capture clinical endpoints of interest more com-
prehensively, and to improve the precision of rate estimates, 
PTs from different SOCs were combined and referred to 
as pharmacovigilance (PV) endpoints. Where feasible and 
appropriate, in order to standardize and facilitate comparabil-
ity, standardized MedDRA queries (SMQs) have been used, 
rather than PV endpoints. A similar approach has been used 
and is described in previous publications.24,26
A composite endpoint of major adverse CV events 
(MACE) was included in the analysis. The composite 
endpoint represented FAEs in the SOC cardiac disorders 
and SOC vascular disorders combined with MI (fatal and 
nonfatal), stroke (fatal and nonfatal), and the sudden death, 
sudden cardiac death, and cardiac death PTs. MACE with 
fatal outcomes are referred to as fatal MACE. The clinical 
endpoint MI was defined by the sub-SMQ MI (broad), while 
for the clinical endpoint of “stroke,” a PV endpoint was used 
in the analysis.
An individual patient may be represented in several PTs 
but was represented only once when the data were displayed 
according to a pooled term, ie, SOC, PV endpoint/SMQ, or 
MACE.
statistical analysis
In order to adjust for treatment durations in the different clini-
cal trials, incidence rates (IRs) were computed as follows: 
the number of patients experiencing an event/patient-years 
at risk. Time at risk was the time from start of treatment to 
onset of a predetermined event. For patients who did not 
experience a specific event, the shortest of either the time 
to death or the time to end of treatment +30 days was used 
(on-treatment analysis).
To measure the strength of the effect, incidence RRs of 
tiotropium versus placebo were calculated on the basis of a 
Cochran–Mantel–Haenszel test stratified by trial. To indicate 
the stability or precision of the effect estimate, the width of 
the 95% confidence intervals (CI) was utilized. An RR.1 
indicates an increased risk with tiotropium, and an RR,1 
indicates a decreased risk with tiotropium.
Results
study population
Of the 28 HandiHaler® and 7 Respimat® trials included in 
this analysis (Table 1), 11,626 patients were treated with 
placebo (8,343 with HandiHaler® and 3,283 with Respimat®) 
and 12,929 with tiotropium (9,647 with HandiHaler® 
and 3,282 with Respimat®), totaling 14,909 (12,469 with 
HandiHaler®; 2,440 with Respimat®) patient-years of 
tiotropium exposure.
Baseline demographics were similar between treatment 
groups (Table 2). The cohort was predominantly male 
(75.4%) with a mean age of 65 years. The prebronchodi-
lator mean FEV
1
 was 1.16 L (41% predicted). Baseline 
concomitant medication use was also similar between treat-
ment groups, with 84.0% of patients receiving respiratory 
medication of any type, and 48.4% receiving CV medica-
tion of any type; 40.7% of patients were receiving LABAs 
and 54.3% ICS. More patients enrolled into the Respimat® 
trials were receiving long-acting inhaled anticholinergics at 
baseline (9.7%) than those enrolled into the HandiHaler® 
trials (1.7%), probably because these were not available or 
not commonly used at the time when most HandiHaler® tri-
als were conducted.
Overall aes
Overall, 62.6% and 65.5% of patients treated with tiotropium 
and placebo, respectively, had at least one AE during the trial, 
and the risk of an AE was significantly reduced with tiotro-
pium (RR [95% CI]: 0.90 [0.87, 0.93]). Tiotropium also sig-
nificantly reduced the risk of SAEs: 21.7% of tiotropium- and 
22.8% of placebo-treated patients had events (RR [95% CI]: 
0.94 [0.89, 0.99]). There was a numerically lower risk of death 
in the tiotropium (4.0%) than in the placebo (4.5%) group (RR 
[95% CI]: 0.90 [0.79, 1.01]). No increased risk of AEs, SAEs, 
and FAEs for the tiotropium group was observed in patients 
with cardiac disorders present at baseline, with all RR,1 
(Table 3). Similar results were obtained when the analysis was 
performed by inhaler type (HandiHaler® or Respimat®) (Table 
3). No significantly increased risk of AEs, SAEs, and FAEs 
for the tiotropium HandiHaler® and Respimat® groups of all 
patients or patients with cardiac disorders, cardiac arrhythmia, 
or renal disorders present at baseline was observed, with the 
exception of the previously described increase in FAEs in 
patients with cardiac arrhythmia at baseline in the tiotropium 
Respimat® group (RR [95% CI]: 3.25 [1.23, 8.60]).11,18 (For 
some of the subgroups, there was at least one trial with patients 
in only one treatment group, and thus no statistics could be 
derived [no RR shown for the subgroups]).
Cardiovascular and respiratory aes
Pooled CV and respiratory terms based on clinical categories 
of public health interest, or on possible pathophysiologic 
associations suggested by either previous published reports 
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Table 2 Patient baseline characteristics
Characteristics HandiHaler® Respimat® Total
Placebo  
n=8,343
Tiotropium 
n=9,647
Placebo  
n=3,283
Tiotropium 
n=3,282
Placebo  
n=11,626
Tiotropium 
n=12,929
age, mean (sD), years 64.63 (8.90) 64.38 (8.76) 64.73 (8.85) 64.64 (8.94) 64.66 (8.89) 64.45 (8.80)
Male, n (%) 6,327 (75.8) 7,315 (75.8) 2,429 (74.0) 2,451 (74.7) 8,756 (75.3) 9,766 (75.5)
Current smoker, n (%) 2,809 (33.7) 3,329 (34.5) 1,238 (37.7) 1,233 (37.6) 4,047 (34.8) 4,562 (35.3)
Baseline spirometry, mean prebronchodilator (sD)
FeV1, l 1.17 (0.46) 1.18 (0.47) 1.11 (0.41) 1.11 (0.41) 1.15 (0.45) 1.16 (0.46)
FeV1, % predicted 41.22 (14.20) 41.66 (14.43) 40.30 (12.45) 40.11 (12.32) 40.96 (13.73) 41.27 (13.94)
FVC, l 2.51 (0.82) 2.49 (0.82) 2.45 (0.79) 2.45 (0.78) 2.49 (0.81) 2.48 (0.81)
FeV1/FVC 0.47 (0.12) 0.48 (0.13) 0.46 (0.11) 0.46 (0.11) 0.47 (0.12) 0.48 (0.12)
Baseline concomitant medicationa, n (%)
any respiratory medication 7,057 (84.6) 8,021 (83.1) 2,767 (84.3) 2,784 (84.8) 9,824 (84.5) 10,805 (83.6)
saMa 3,295 (39.5) 3,709 (38.4) 982 (29.9) 1,040 (31.7) 4,277 (36.8) 4,749 (36.7)
laMa 150 (1.8) 150 (1.6) 325 (9.9) 313 (9.5) 475 (4.1) 463 (3.6)
β2 agonists 6,199 (74.3) 6,789 (70.4) 2,440 (74.3) 2,469 (75.2) 8,639 (74.3) 9,258 (71.6)
short acting 5,044 (60.5) 5,630 (58.4) 1,816 (55.3) 1,815 (55.3) 6,860 (59.0) 7,445 (57.6)
long acting 3,340 (40.0) 3,520 (36.5) 1,538 (46.8) 1,597 (48.7) 4,878 (42.0) 5,117 (39.6)
steroids 4,731 (56.7) 5,379 (55.8) 1,844 (56.2) 1,821 (55.5) 6,575 (56.6) 7,200 (55.7)
ICs 4,564 (54.7) 5,184 (53.7) 1,807 (55.0) 1,785 (54.4) 6,371 (54.8) 6,969 (53.9)
OCs 547 (6.6) 635 (6.6) 100 (3.0) 100 (3.0) 647 (5.6) 735 (5.7)
ICs+laBa 2,687 (32.2) 2,904 (30.1) 1,358 (41.4) 1,395 (42.5) 4,045 (34.8) 4,299 (33.3)
Xanthines 1,705 (20.4) 2,103 (21.8) 638 (19.4) 667 (20.3) 2,343 (20.2) 2,770 (21.4)
Oxygen 399 (4.8) 414 (4.3) 63 (1.9) 54 (1.6) 462 (4.0) 468 (3.6)
Mucolytics 411 (4.9) 473 (4.9) 228 (6.9) 237 (7.2) 639 (5.5) 710 (5.5)
Other respiratory medication 178 (2.1) 196 (2.0) 35 (1.1) 46 (1.4) 213 (1.8) 242 (1.9)
any CV medication 4,599 (55.1) 5,283 (54.8) 1,690 (51.5) 1,723 (52.5) 6,289 (54.1) 7,006 (54.2)
Cardiac disorder presentb, n (%) 2,048 (25.8) 2,257 (26.8) 852 (26.0) 891 (27.1) 2,900 (25.8) 3,148 (26.9)
Cardiac arrhythmia presentb, n (%) 611 (7.7) 719 (8.5) 350 (10.7) 428 (13.0) 961 (8.6) 1,147 (9.8)
renal disorder presentb,c, n (%) 127 (1.6) 151 (1.8) 54 (1.6) 68 (2.1) 181 (1.6) 219 (1.9)
Notes: aIncludes patients with combination therapy. bexcluded study 205.257, for which diagnoses could not be mapped. clisted as concomitant disease (any comorbidity 
at baseline coded to renal and/or urinary disorders).
Abbreviations: CV, cardiovascular; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity, ICs, inhaled corticosteroid; laBa, long-acting β2 agonist; laMa, 
long-acting muscarinic antagonist; OCs, oral corticosteroid; saMa, short-acting muscarinic antagonist; sD, standard deviation.
or potential biologic mechanisms, are reported in the pres-
ent analysis, with AEs and SAEs shown in Tables 4 and 5, 
respectively.
In total, 8.0% of patients had at least one cardiac AE 
during the study, and 6.2% of patients had at least one 
vascular AE (Table 4). Tiotropium was not associated with 
an increased risk of cardiac AEs (RR [95% CI]: 0.93 [0.85, 
1.02]) or vascular AEs (RR [95% CI]: 0.96 [0.87, 1.07]) 
(Table 4). There was no indication of an increased risk of MI 
or stroke (RR [95% CI]: 0.85 [0.67, 1.09] or RR [95% CI]: 
1.02 [0.79, 1.32]). There was no increased risk associated 
with tiotropium for ischemic heart disease and hypertension 
(RR [95% CI]: 1.01 [0.85, 1.19] and RR [95% CI]: 0.93 
[0.82, 1.06]). Respiratory, thoracic, and mediastinal disorders 
were common (41.9% of patients) and were associated with 
a significantly decreased risk with tiotropium (RR [95% 
CI]: 0.81 [0.78, 0.85]), including for COPD exacerbations 
and respiratory failure (RR [95% CI]: 0.78 [0.75, 0.81] and 
RR [95% CI]: 0.81 [0.67, 0.97]). Similar results were 
obtained when the HandiHaler® and Respimat® groups were 
analyzed separately, with no increased risk of cardiac, vas-
cular, and respiratory, thoracic, and mediastinal disorders or 
stroke in the tiotropium groups except for an increased risk 
of ischemic heart disease in the tiotropium Respimat® group 
(RR [95% CI]: 1.61 [1.04, 2.49]) (Table 4).
Overall, 4.4% of patients had at least one cardiac SAE 
during the study, and 1.3% of patients had at least one 
vascular SAE (Table 5). Tiotropium was associated with a 
decreased risk for cardiac SAEs (RR [95% CI]: 0.86 [0.76, 
0.97]) and a similar risk for vascular SAEs (RR [95% CI]: 
1.05 [0.84, 1.32]) (Table 5) compared with placebo. Tiotro-
pium was not associated with an increased risk for the SAEs 
of ischemic heart disease, MI, or stroke (RR [95% CI]: 0.85 
[0.67, 1.08], RR [95% CI]: 0.87 [0.68, 1.13], or RR [95% 
CI]: 1.07 [0.80, 1.42], respectively). Respiratory, thoracic, 
and mediastinal disorder SAEs were common (occurring in 
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Tiotropium: pooled safety analysis
13% of patients), and were associated with a significantly 
decreased risk with tiotropium (RR [95% CI]: 0.84 [0.78, 
0.91]), including for COPD exacerbations and respiratory 
failure (RR [95% CI]: 0.83 [0.76, 0.90] and RR [95% CI]: 
0.77 [0.63, 0.94]). Numerical differences for tiotropium 
Respimat® and HandiHaler® versus placebo could be 
observed for single terms; however, overall similar results 
were obtained for SAEs occurring when the HandiHaler® and 
Respimat® groups were analyzed separately (Table 5).
Major adverse CV events
MACE and fatal MACE are shown in Table 6. There was no 
evidence of increased risk for MACE (RR [95% CI]: 0.87 
[0.75, 1.01]) or fatal MACE (including death unknown, RR 
[95% CI]: 0.90 [0.74, 1.10]) for the tiotropium group. Simi-
larly, no increased risk was observed with the tiotropium 
HandiHaler® and Respimat® groups separately (Table 6).
anticholinergic events
Potential anticholinergic AEs and SAEs are depicted in 
Tables 7 and 8, respectively. The PV endpoints shown 
are a summary of AEs for presumed, potential, or hypo-
thetical events that may be a consequence of anticholinergic 
pharmacology.
Dry mouth (RR [95% CI]: 2.35 [1.99, 2.77]), constipation 
(RR [95% CI]: 1.28 [1.06, 1.54]), and urinary retention (RR 
[95% CI]: 1.56 [1.03, 2.36]) occurred more frequently with 
tiotropium versus placebo, with dry mouth being the most 
common AE, occurring in 4% of patients in the tiotropium 
group (Table 7). Gastrointestinal obstruction, dyspepsia, 
dysuria, and gastroesophageal reflux also increased with 
tiotropium use. The incidence of glaucoma or the worsening 
of an existing glaucoma at baseline was not increased with 
tiotropium, as shown by an RR close to 1 (RR [95% CI]: 0.97 
[0.62, 1.52]). There was no increased risk for metabolism and 
nutrition, nervous system, and psychiatric AEs (Table 7). 
Potential anticholinergic SAEs were not associated with 
an increased risk with tiotropium (Table 8). Similar results 
were obtained for anticholinergic AEs and SAEs occurring 
when the HandiHaler® and Respimat® groups were analyzed 
separately (data not shown).
Fatal events
As noted earlier, there was a numerically lower risk of death 
in the tiotropium group (RR [95% CI]: 0.90 [0.79, 1.01]). 
Figure 1 depicts all-cause FAEs by trial. Most individual tri-
als were associated with a wide CI, a few of which exhibited 
higher IRs for the tiotropium group. T
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Table 7 Irs (per 100 patient-years) and rrs for potential anticholinergic aes
Placebo n=11,626 Tiotropium n=12,929 RR (95% CI)
n (%) IR n (%) IR
Eye disordersa 418 (3.6) 3.05 471 (3.6) 3.09 1.01 (0.88, 1.15)
glaucomab 38 (0.3) 0.27 41 (0.3) 0.26 0.97 (0.62, 1.52)
Vision blurredc 67 (0.6) 0.47 62 (0.5) 0.39 0.80 (0.57, 1.14)
Gastrointestinal disordersa 1,569 (13.5) 12.65 2,082 (16.1) 15.58 1.20 (1.13, 1.29)d
abdominal painc 206 (1.8) 1.47 246 (1.9) 1.57 1.04 (0.86, 1.25)
Constipationc 185 (1.6) 1.32 264 (2.0) 1.69 1.28 (1.06, 1.54)d
Dry mouthc 196 (1.7) 1.40 519 (4.0) 3.39 2.35 (1.99, 2.77)d
Dyspepsiac 376 (3.2) 2.73 515 (4.0) 3.38 1.21 (1.06, 1.38)d
Dysphagiac 24 (0.2) 0.17 33 (0.3) 0.21 1.21 (0.71, 2.08)
Gastroesophageal reflux diseasec 261 (2.2) 1.87 374 (2.9) 2.42 1.25 (1.06, 1.46)d
gastrointestinal obstructione 33 (0.3) 0.23 64 (0.5) 0.40 1.76 (1.16, 2.69)d
stomatitisc 36 (0.3) 0.25 49 (0.4) 0.31 1.12 (0.73, 1.73)
Metabolism and nutrition disordersa 639 (5.5) 4.76 663 (5.1) 4.41 0.92 (0.83, 1.03)
Dehydrationc 32 (0.3) 0.22 40 (0.3) 0.25 1.14 (0.71, 1.82)
hyperglycemia/new-onset diabetes mellitusf 212 (1.8) 1.52 225 (1.7) 1.44 0.94 (0.78, 1.13)
Nervous system disordersa 1,051 (9.0) 8.02 1,233 (9.5) 8.51 1.02 (0.94, 1.11)
Dizzinessc 280 (2.4) 2.01 333 (2.6) 2.15 1.03 (0.88, 1.21)
headachec 398 (3.4) 2.88 475 (3.7) 3.09 1.00 (0.88, 1.14)
sleep disturbancec 204 (1.8) 1.46 242 (1.9) 1.55 1.05 (0.87, 1.26)
syncopec 72 (0.6) 0.51 85 (0.7) 0.54 1.06 (0.77, 1.45)
Psychiatric disordersa 533 (4.6) 3.90 615 (4.8) 4.06 1.01 (0.90, 1.14)
anxiety symptoms/fearsc 194 (1.7) 1.38 203 (1.6) 1.29 0.89 (0.73, 1.09)
Cognitive impairmentc 2 (0.0) 0.01 1 (0.0) 0.01 0.46 (0.04, 5.09)
Confusionc 22 (0.2) 0.15 18 (0.1) 0.11 0.70 (0.37, 1.31)
Insomniac 184 (1.6) 1.31 227 (1.8) 1.45 1.10 (0.90, 1.34)
restlessnessc 13 (0.1) 0.09 12 (0.1) 0.08 0.65 (0.29, 1.46)
Depression and self-injuryg 173 (1.5) 1.23 209 (1.6) 1.33 1.08 (0.88, 1.32)
Renal and urinary disordersa 341 (2.9) 2.46 396 (3.1) 2.56 1.04 (0.90, 1.20)
Dysuriac 23 (0.2) 0.16 52 (0.4) 0.33 2.07 (1.26, 3.39)d
renal failurec 68 (0.6) 0.48 73 (0.6) 0.46 0.97 (0.70, 1.36)
Urinary retentionc 36 (0.3) 0.25 62 (0.5) 0.39 1.56 (1.03, 2.36)d
Urinary tract infectionc 287 (2.5) 2.06 350 (2.7) 2.26 1.08 (0.92, 1.26)
Notes: aPrimary sOC. bsMQ glaucoma (narrow). cPV endpoint (see Table s1 for details). dSignificantly different from 1. esMQ gastrointestinal perforation, ulceration, 
hemorrhage, or obstruction. fsMQ hyperglycemia/new-onset diabetes mellitus (narrow). gsMQ depression and self-injury (excluding suicide and self-injury) (narrow).
Abbreviations: AE, adverse event; CI, confidence interval; IR, incidence rate; PV, pharmacovigilance; RR, rate ratio; SMQ, standardized Medical Dictionary for Regulatory 
activities queries; sOC, system organ class.
Table 9 depicts the most common causes of death 
according to SOC (with a frequency of $3% of total FAEs 
within any of the treatment arms in either study pool, ie, 
HandiHaler®, Respimat®, or both combined) and PT (with a 
frequency of $10 FAEs within the pooled analysis). Respi-
ratory, thoracic, and mediastinal disorders were the most 
common cause of death (occurring in 1.2% of patients), and 
were associated with a reduced overall risk for tiotropium 
(RR [95% CI]: 0.76 [0.61, 0.96]). None of the SOCs were 
associated with a significantly increased risk for tiotropium. 
When the HandiHaler® and Respimat® groups were analyzed 
separately, neither tiotropium HandiHaler® nor tiotropium 
Respimat® was associated with significantly increased FAEs 
according to SOC, while the risk associated with tiotropium 
HandiHaler® was additionally decreased for respiratory, 
thoracic, and mediastinal disorders as well as for cardiac 
disorders (Table 9).
Discussion
Long-term safety evaluation of treatment is essential for 
prescribing physicians. The present safety analysis reflects 
the large safety database of placebo-controlled studies with 
tiotropium, a long-established (over 10 years) treatment 
for COPD. This analysis of 24,555 patients, which adds 
to the last comprehensive safety review of 2009 (17,014 
patients),26 includes data with Respimat® – in all, 28 tiotro-
pium HandiHaler® and 7 tiotropium Respimat® trials (com-
pared with 26 HandiHaler® trials from the previous safety 
review). The recent TIOSPIR™ trial did not show any 
relevant differences between tiotropium HandiHaler® and 
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Table 8 Irs (per 100 patient-years) and rrs for potential anticholinergic saes
Placebo n=11,626 Tiotropium n=12,929 RR (95% CI)
n (%) IR n (%) IR
Eye disordersa 33 (0.3) 0.23 38 (0.3) 0.24 1.07 (0.67, 1.71)
glaucomab 1 (0.0) 0.01 2 (0.0) 0.01 1.85 (0.17, 20.37)
Vision blurredc 1 (0.0) 0.01 1 (0.0) 0.01 0.92 (0.06, 14.77)
Gastrointestinal disordersa 266 (2.3) 1.90 284 (2.2) 1.82 0.96 (0.81, 1.14)
abdominal painc 28 (0.2) 0.20 30 (0.2) 0.19 0.94 (0.56, 1.57)
Constipationc 5 (0.0) 0.04 7 (0.1) 0.04 1.28 (0.40, 4.08)
Dyspepsiac 28 (0.2) 0.20 26 (0.2) 0.16 0.86 (0.50, 1.47)
Dysphagiac 4 (0.0) 0.03 5 (0.0) 0.03 1.12 (0.30, 4.24)
Gastroesophageal reflux diseasec 14 (0.1) 0.10 16 (0.1) 0.10 1.06 (0.51, 2.19)
gastrointestinal obstructiond 27 (0.2) 0.19 45 (0.3) 0.28 1.51 (0.93, 2.44)
stomatitisc 0 (0.0) 0.00 2 (0.0) 0.01
Metabolism and nutrition disordersa 77 (0.7) 0.54 71 (0.5) 0.45 0.82 (0.59, 1.13)
Dehydrationc 12 (0.1) 0.08 20 (0.2) 0.13 1.47 (0.71, 3.07)
hyperglycemia/new-onset diabetes mellituse 22 (0.2) 0.15 29 (0.2) 0.18 1.14 (0.65, 2.00)
Nervous system disordersa 205 (1.8) 1.46 222 (1.7) 1.41 0.98 (0.81, 1.19)
Dizzinessc 26 (0.2) 0.18 23 (0.2) 0.14 0.82 (0.47, 1.43)
headachec 5 (0.0) 0.04 5 (0.0) 0.03 0.93 (0.27, 3.20)
sleep disturbancec 5 (0.0) 0.04 0 (0.0) 0.00 0.00
syncopec 23 (0.2) 0.16 40 (0.3) 0.25 1.57 (0.94, 2.64)
Psychiatric disordersa 58 (0.5) 0.41 46 (0.4) 0.29 0.71 (0.48, 1.04)
anxiety symptoms/fearsc 10 (0.1) 0.07 7 (0.1) 0.04 0.62 (0.23, 1.63)
Confusionc 5 (0.0) 0.04 5 (0.0) 0.03 0.93 (0.27, 3.27)
Insomniac 1 (0.0) 0.01 0 (0.0) 0.00 0.00
restlessnessc 2 (0.0) 0.01 0 (0.0) 0.00 0.00
Depression and self-injuryf 20 (0.2) 0.14 15 (0.1) 0.09 0.68 (0.35, 1.31)
Renal and urinary disordersa 84 (0.7) 0.59 108 (0.8) 0.68 1.16 (0.87, 1.55)
Dysuriac 0 (0.0) 0.00 3 (0.0) 0.02
renal failurec 32 (0.3) 0.22 46 (0.4) 0.29 1.31 (0.83, 2.06)
Urinary retentionc 12 (0.1) 0.08 24 (0.2) 0.15 1.87 (0.93, 3.73)
Urinary tract infectionc 28 (0.2) 0.20 37 (0.3) 0.23 1.19 (0.73, 1.95)
Notes: aPrimary sOC. bsMQ glaucoma (narrow). cPV endpoint (see Table s1 for details). dsMQ gastrointestinal perforation, ulceration, hemorrhage, or obstruction. esMQ 
hyperglycemia/new-onset diabetes mellitus (narrow). fsMQ depression and self-injury (excluding suicide and self-injury) (narrow).
Abbreviations: Ir, incidence rate; PV, pharmacovigilance; rr, rate ratio; sae, serious adverse event; sMQ, standardized Medical Dictionary for regulatory activities 
queries; sOC, system organ class.
tiotropium Respimat®, in particular relating to safety. This 
led to the development of the present pooled safety analysis, 
and provides the justification for the pooling of both inhaler 
types. Additionally, the pooled studies had similar entry 
criteria, assessment procedures, and data collection methods; 
the patient baseline characteristics were also comparable 
between the HandiHaler® and Respimat® trials.
This pooled safety analysis shows that IRs for overall 
AEs and SAEs were significantly lower in the tiotropium 
group compared with those in the placebo group, while the 
incidence of FAEs was numerically lower in the tiotropium 
group. In the tiotropium HandiHaler® group, IRs were signifi-
cantly lower for all AEs, while for the tiotropium Respimat® 
group, AEs were significantly lower and SAEs and FAEs 
were comparable to the placebo group. Overall, these results 
demonstrate that both tiotropium Respimat® and tiotropium 
HandiHaler® do not increase the risk of an AE. Furthermore, 
there was no evidence to show an increased risk of cardiac 
or vascular events, including MACE, with either tiotropium 
HandiHaler® or tiotropium Respimat®. A higher incidence 
of ischemic heart disease for tiotropium versus placebo was 
seen in the Respimat® group but not in the HandiHaler® 
group; however, the IRs were lower in the placebo Respi-
mat® group than in the placebo HandiHaler® group (IR: 1.25 
versus 1.89), and no significant difference in the risk of MI 
was seen between the Respimat® and HandiHaler® groups 
in the TIOSPIR™ trial.
FAEs by SOC and PT did not reveal an imbalance between 
the placebo and tiotropium groups, either pooled or by inhaler 
type. As expected, known anticholinergic AEs (such as dry 
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mouth, constipation, intestinal obstruction, and urinary reten-
tion) were more frequent in the tiotropium versus placebo 
groups, although SAEs were not. The large patient database 
size and large tiotropium exposure in terms of patient years 
provide a robust estimate of the IRs for these effects and 
allow a sound assessment of risks and benefits with tiotropium 
HandiHaler® and Respimat® in patients with COPD.
We have carried out further analysis on patients with 
renal impairment. The results were presented at the European 
Respiratory Society Annual Congress 2014.31 The safety of 
tiotropium was analyzed in trials where creatinine clearance 
was reported at baseline. Incidence RRs of AEs, SAEs, and 
FAEs with tiotropium HandiHaler® or Respimat® versus 
placebo showed no association with mild to moderately 
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impaired renal function (10,805 patients were evaluable: 
n=4,282 in HandiHaler® trials; n=6,523 in Respimat® trials). 
Results for severe renal impairment were, however, limited 
owing to low patient numbers (n=52).
The results reported here support the 2009 safety 
analysis,26 which showed a reduced risk of overall AEs, 
SAEs, and FAEs with tiotropium HandiHaler®. The safety 
results within the Kesten et al26 analysis were also consistent 
with those seen in the UPLIFT® trial (with the analyses for 
HandiHaler® trials being driven predominantly by the data 
from UPLIFT®, based on large patient numbers and 4-year 
trial length), and indicated a reduction in cardiac AEs and 
MACE associated with tiotropium, and no increased risk of 
vascular AEs. Our analysis presents a numerically reduced 
risk of cardiac AEs with tiotropium in both inhalers. The risk 
of respiratory disorders was significantly reduced in both 
the Kesten et al26 and our analyses, while the recognized 
anticholinergic effects were higher with tiotropium use. 
A limitation of comparing the results of the present analysis 
with those of the Kesten et al26 pooled analysis is that the 
latter included all but two of the HandiHaler® trials included 
in our pooled analysis, so that its results are driven mainly 
by the findings from the HandiHaler® trials (28 HandiHaler® 
trials versus 7 Respimat® trials).
The results from this safety review support the recent find-
ings of the largest randomized, double-blind, parallel-group 
trial performed to date in COPD, involving 17,135 patients – the 
TIOSPIR™ trial.29 TIOSPIR™ showed that tiotropium 
Respimat® (2.5 or 5 µg once daily) had a similar safety 
profile and exacerbation efficacy as tiotropium HandiHaler® 
(18 µg once daily) (risk of death HR [95% CI]: 0.96 [0.84, 
1.09] for Respimat® 5 µg and 1.00 [0.87, 1.14] for Respimat® 
2.5 µg; risk of first exacerbation HR [95% CI]: 0.98 [0.93, 
1.03] for Respimat® 5 µg). Our analysis, similar to earlier 
analyses, found an increased risk of FAEs in patients with 
cardiac arrhythmia at baseline for the tiotropium Respimat® 
group. This finding may be due to an unusually low IR in the 
placebo Respimat® group (1.83), compared with an IR of 6.08 
in the active treatment group. The corresponding IRs in the 
HandiHaler® database were higher (placebo: 6.80, tiotro-
pium: 5.24). Direct comparison of tiotropium HandiHaler® 
and Respimat® in the TIOSPIR™ trial, which was powered to 
assess the all-cause mortality noninferiority, did not indicate a 
mortality imbalance for patients with cardiac arrhythmias at 
baseline (RR [95% CI]: 0.81 [0.58, 1.12] for tiotropium 
Respimat® 5 µg versus HandiHaler®).29 Furthermore, the 
accompanying editorial by Jenkins32 concluded that both 
HandiHaler® and Respimat® have equal safety profiles.
The findings of our analysis contrast with retrospective 
analyses regarding CV events and inhaled anticholinergics, 
which suggested that CV deaths were increased with inhaled 
anticholinergic, in particular with ipratropium.33,34 Limitations 
to these meta-analyses have been described previously,24 
and include improper design due to lack of data, errors in 
article identification and data extraction, as well as improper 
accounting for differential trial discontinuation. A mortality 
imbalance was seen with tiotropium Respimat® in a pooled 
analysis of three 1-year trials and one 6-month trial,11,18 and 
with subsequent meta-analyses.19–22 These meta-analyses 
were based on the same trials as the present review, but were 
carried out differently. In the Singh et al22 and Karner et al20 
meta-analyses, which included five randomized, controlled 
trials (NCT00239473,35 NCT00240435,35 NCT00168844,36 
NCT00168831,36 and NCT00387088), tiotropium Respimat® 
was associated with an increased risk of FAEs. These analy-
ses were limited due to imprecise estimates owing to fairly 
low event rates and were performed on published aggregated 
on-treatment data, including the higher 10 µg dose, rather 
than using individual patient data, possibly leading to bias.21 
The Dong et al19 meta-analysis, which also associated tiotro-
pium Respimat® with a higher risk of FAEs, in particular for 
CV death, in patients with severe COPD and in those at a 
higher daily dose (10 µg), only used three Respimat® trials 
(NCT00168844,36 NCT00168831,36 and NCT0038708812). 
All of the trials included in these meta-analyses were also 
included in the current analysis, which totaled seven Respi-
mat® trials (all placebo-controlled trials available to date). 
The high number of patients and patient-years of exposure 
to tiotropium included in our review, and especially the 
use of individual patient data, ensures the robustness of the 
analysis.
Although most prospective, randomized, double-blind, 
clinical trials with tiotropium HandiHaler® and Respimat® 
in COPD have been conducted by Boehringer Ingelheim and 
are included in this analysis, a few other studies have been 
carried out. The Investigating New Standards for Prophylaxis 
In Reduction of Exacerbations (INSPIRE) study observed 
an increase in mortality in the tiotropium (HandiHaler®) 
group compared with the salmeterol and fluticasone groups. 
However, the interpretation beyond the primary exacerba-
tion endpoint should be done with caution as the withdrawal 
of the run-in medication, salmeterol and oral prednisolone 
(30 mg), at the time of randomization may also have affected 
the outcome and results of this trial.37,38 Additional studies 
of tiotropium HandiHaler® were performed in an open-label 
fashion, for which patient-level data were not available.39,40
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Tiotropium: pooled safety analysis
Pooling clinical data into meta-analyses includes such limi-
tations as differences in trial populations, trial design, and phy-
sician diagnostic reporting. However, the present safety review 
reduced these limitations by analyzing the data on a patient 
level and controlling for differences in exposure between 
treatment groups, therefore reducing bias and confounding. In 
addition, the analysis of patient-level data also allows grouping 
of AEs, such as SMQs, PV endpoints, and subgroup analyses 
defined by potential risk factors. Potential problems in com-
bining studies have been minimized because the trials were 
conducted using consistent inclusion and exclusion criteria, 
the same diagnostic criteria, and nearly identical approaches 
to data collection. A potential limitation may arise from the 
accuracy of causes of death reported by investigators, as only 
a few trials had an adjudication committee (studies 205.235 
and 205.372). However, for consistency with data capture for 
AEs, SAEs, and other trials, the investigator-reported causes 
were used for the pooled analysis rather than the adjudicated 
terms from the clinical endpoints committee.
In our analysis, some HandiHaler® trials (such as UPLIFT® 
and 205.266) as well as the Respimat® trials had relatively 
broad inclusion criteria (including patients with stable 
cardiac disorders), and allowed concomitant respiratory 
medication including ICS, LABAs, and theophylline. 
Therefore, the patient population analyzed here gener-
ally reflects real-world heterogeneous populations and 
phenotypes of patients with COPD, as far as is possible 
in randomized, controlled trials. The absolute rates of 
FAEs observed for the groups reported in this analysis 
(IR/100 patient-years: 3.71 and 3.27 for the placebo and 
tiotropium groups, respectively) are comparable with 
those of mortality in general in COPD for which observed 
mortality IRs are 1.7–2.2 for Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) Stage 2 patients and 
3.07–4.29 for GOLD Stage 3 and 4 patients.41,42 Furthermore, 
the increased size of the safety database, pooling 35 stud-
ies to include 12,929 tiotropium-treated patients, providing 
14,909 patient-years’ exposure to tiotropium, provides a 
robust dataset.
In summary, the present analysis describes the pooled 
safety data for tiotropium HandiHaler® (28 trials) and Respi-
mat® (7 trials), as well as by inhaler type, in 24,555 patients 
and 14,909 patient-years of exposure to tiotropium. The results 
indicate that tiotropium, given via either HandiHaler® or Respi-
mat®, does not increase the overall risks of AEs, SAEs, FAEs, 
or CV events. Given the evidence, provided by the TIOSPIR™ 
trial, that both have an equal safety profile, and given their 
established efficacy in terms of bronchodilation, reduction 
in exacerbations, and  improvement in HRQoL, physicians 
may consider tiotropium in either formulation depending on 
 availability and their preference or that of the patient.
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Supplementary material
Table S1 PV endpoint definition
PV endpoint/SMQ MedDRA PT
abdominal pain abdominal pain; abdominal pain lower; abdominal pain upper; abdominal rebound tenderness; abdominal 
tenderness; epigastric discomfort; gastrointestinal pain
aneurysm aneurysm; aneurysm arteriovenous; aneurysm ruptured; aortic aneurysm; aortic aneurysm rupture; aortic 
aneurysm syphilitic; aortic dissection; aortic dissection rupture; aortic intramural hematoma; aortic stent 
insertion; artery dissection; cardiac aneurysm; carotid aneurysm rupture; cerebral aneurysm ruptured syphilitic; 
Charcot−Bouchard microaneurysms; coronary artery aneurysm; coronary artery dissection; dissecting 
coronary artery aneurysm; femoral artery aneurysm; femoral artery dissection; hemorrhage coronary artery; 
hepatic artery aneurysm; infective aneurysm; intracranial aneurysm; mycotic aneurysm; peripheral artery 
aneurysm; peripheral artery dissection; pulmonary artery aneurysm; renal aneurysm; renal artery dissection; 
retinal aneurysm; ruptured cerebral aneurysm; splenic artery aneurysm; subclavian artery aneurysm; superior 
vena cava dilatation; venous aneurysm
anxiety symptoms/fears acrophobia; activation syndrome; acute stress disorder; agitation; agitation neonatal; agoraphobia; animal 
phobia; anticipatory anxiety; anxiety; anxiety disorder; anxiety disorder due to a general medical condition; 
arachnophobia; autophobia; Burnout syndrome; claustrophobia; compulsions; compulsive hand washing; 
dysmorphophobia; emetophobia; fear; fear of animals; fear of closed spaces; fear of crowded places; fear of death; 
fear of disease; fear of eating; fear of falling; fear of needles; fear of open spaces; fear of pregnancy; fear of weight 
gain; generalized anxiety disorder; haphephobia; hydrophobia; limited symptom panic attack; nervousness; 
neurosis; noctiphobia; nocturnal fear; nosophobia; obsessive thoughts; obsessive-compulsive disorder; 
ochlophobia; osmophobia; pediatric autoimmune neuropsychiatric disorders associated with streptococcal 
infection; panic attack; panic disorder; panic disorder with agoraphobia; panic disorder without agoraphobia; panic 
reaction; paruresis; performance fear; phagophobia; pharmacophobia; phobia; phobia of driving; phobia of exams; 
phobia of flying; phobic avoidance; phonophobia; photaugiaphobia; post-traumatic stress disorder; postpartum 
neurosis; postpartum stress disorder; social fear; social phobia; stress; tension; thanatophobia
Cardiac arrest atrioventricular dissociation; cardiac arrest; cardiac death; cardiac massage; cardiorespiratory arrest; 
cardiogenic shock; pulseless electrical activity; resuscitation
Cardiac failure 
(sMQ cardiac failure 
[narrow])
acute left ventricular failure; acute pulmonary edema; acute right ventricular failure; cardiac asthma; cardiac 
failure; cardiac failure acute; cardiac failure chronic; cardiac failure congestive; cardiac failure high output; 
cardiogenic shock; cardiopulmonary failure; cardiorenal syndrome; chronic left ventricular failure; chronic 
right ventricular failure; cor pulmonale; cor pulmonale acute; cor pulmonale chronic; ejection fraction 
decreased; hepatic congestion; hepatojugular reflux; left ventricular failure; low cardiac output syndrome; 
neonatal cardiac failure; pulmonary edema; pulmonary edema neonatal; right ventricular failure; ventricular 
failure
Cognitive impairment Cognitive disorder
Confusion Confusion postoperative; confusional state; disorientation
Constipation Colonic pseudo-obstruction; constipation; feces hard; infrequent bowel movements; postprocedural 
constipation
COPD exacerbation Chronic obstructive pulmonary disease; infective exacerbation of chronic obstructive airways disease; 
obstructive airways disorder
Dehydration Dehydration
Depression and self-
injury (sMQ depression 
and self-injury 
(excluding suicide and 
self-injury) (narrow)
activation syndrome; adjustment disorder with depressed mood; adjustment disorder with mixed anxiety 
and depressed mood; agitated depression; anhedonia; antidepressant therapy; childhood depression; 
decreased interest; depressed mood; depression; depression postoperative; depressive symptom; dysphoria; 
dysthymic disorder; electroconvulsive therapy; feeling guilty; feeling of despair; feelings of worthlessness; 
major depression; menopausal depression; postpartum depression
Dizziness Dizziness; dizziness exertional; dizziness postural; vertigo; vertigo positional
Dry mouth aptyalism; dry mouth; dry throat; lip dry
Dyspepsia (including 
reflux)
abdominal discomfort; dyspepsia; epigastric discomfort; esophageal pain; esophagitis; gastritis; 
gastroesophageal reflux disease; reflux gastritis; reflux laryngitis
Dysphagia Dysphagia; esophageal hypomotility; malignant dysphagia
Dysuria Dysuria; strangury
gastroesophageal 
reflux disease
Dyspepsia; esophageal pain; esophagitis; reflux gastritis; gastroesophageal reflux; disease; reflux laryngitis
(Continued)
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Table S1 (Continued)
PV endpoint/SMQ MedDRA PT
gastrointestinal 
obstruction (sMQ 
gastrointestinal 
perforation, ulceration, 
hemorrhage, or 
obstruction)
anal stenosis; anastomotic stenosis; anastomotic ulcer, obstructive; anorectal stenosis; barium impaction; 
colonic obstruction; colonic stenosis; distal ileal obstruction syndrome; distal intestinal obstruction syndrome; 
duodenal obstruction; duodenal scarring; duodenal stenosis; duodenal ulcer perforation, obstructive; duodenal 
ulcer, obstructive; esophageal obstruction; esophageal stenosis; fibrosing colonopathy; gastric stenosis; gastric 
ulcer hemorrhage, obstructive; gastric ulcer perforation, obstructive; gastric ulcer, obstructive; gastrointestinal 
anastomotic leak; gastrointestinal hypomotility; gastrointestinal motility disorder; gastrointestinal obstruction; 
gastrointestinal stenosis; ileal stenosis; impaired gastric emptying; intestinal obstruction; intestinal stenosis; jejunal 
tenosis; large intestinal obstruction; large intestinal obstruction reduction; large intestinal stricture; necrotizing 
colitis; necrotizing gastritis; necrotizing esophagitis; neonatal intestinal obstruction; obstruction gastric; peptic ulcer 
perforation, obstructive; peptic ulcer, obstructive; prepyloric stenosis; rectal obstruction; rectal stenosis; small 
intestinal bacterial overgrowth; small intestinal obstruction; small intestinal stenosis
glaucoma (sMQ 
glaucoma) (narrow)
angle closure glaucoma; borderline glaucoma; developmental glaucoma; diabetic glaucoma; fundoscopy 
abnormal; glaucoma; glaucoma drug therapy; glaucoma surgery; glaucoma traumatic; glaucomatocyclitic 
crises; glaucomatous optic disc atrophy; gonioscopy abnormal; halo vision; intraocular pressure; fluctuation; 
intraocular pressure increased; intraocular pressure test abnormal; iridotomy; loss of visual contrast 
sensitivity; normal tension glaucoma; ocular hypertension; open angle glaucoma; ophthalmic fluid drainage; 
optic discs blurred; optic nerve cup/disc ratio increased; optic nerve cupping; phacolytic glaucoma; 
phacotrabeculectomy; pigmentary glaucoma; pupillary light reflex tests abnormal; slit-lamp tests abnormal; 
trabeculectomy; trabeculoplasty; visual field tests abnormal
headache Basilar migraine; chronic paroxysmal hemicrania; cluster headache; complicated migraine; drug withdrawal 
headache; headache; migraine; migraine with aura; migraine without aura; ophthalmoplegic migraine; 
post-traumatic headache; postictal headache; retinal migraine; sUnCT syndrome; sinus headache; status 
migrainosus; temporomandibular joint syndrome; tension headache; typical aura without headache
hyperglycemia/new-
onset diabetes mellitus 
(sMQ hyperglycemia/
new-onset diabetes 
mellitus) (narrow)
Blood 1,5-anhydroglucitol decreased; blood glucose increased; diabetes complicating pregnancy; diabetes 
mellitus; diabetes mellitus inadequate control; diabetes with hyperosmolarity; diabetic coma; diabetic 
hyperglycemic coma; diabetic hyperosmolar coma; diabetic ketoacidosis; diabetic ketoacidotic hyperglycemic 
coma; fructosamine increased; gestational diabetes; glucose tolerance impaired; glucose tolerance impaired 
in pregnancy; glucose urine present; glycosuria; glycosuria during pregnancy; glycosylated hemoglobin increased; 
hyperglycemia; hyperglycemic hyperosmolar nonketotic syndrome; impaired fasting glucose; insulin resistance; 
insulin resistance syndrome; insulin-resistant diabetes; insulin-requiring Type 2 diabetes mellitus; ketoacidosis; 
ketonuria; ketosis; latent autoimmune diabetes in adults; metabolic syndrome; neonatal diabetes mellitus; 
pancreatogenous diabetes; Type 1 diabetes mellitus; Type 2 diabetes mellitus; urine ketone body present
hypertension accelerated hypertension; blood pressure ambulatory increased; blood pressure diastolic increased; 
blood pressure inadequately controlled; blood pressure increased; blood pressure orthostatic increased; 
blood pressure systolic increased; diastolic hypertension; endocrine hypertension; essential hypertension; 
hypertension; hypertensive angiopathy; hypertensive cardiomegaly; hypertensive cardiomyopathy; 
hypertensive crisis; hypertensive emergency; hypertensive encephalopathy; hypertensive heart 
disease; hypertensive nephropathy; labile hypertension; liddle’s syndrome; malignant hypertension; 
malignant hypertensive heart disease; malignant renal hypertension; mean arterial pressure increased; 
neurogenic hypertension; orthostatic hypertension; paradoxical pressor response; procedural hypertension; 
renal hypertension; renovascular hypertension; secondary hypertension; systolic hypertension
Insomnia Initial insomnia; insomnia; middle insomnia; poor quality sleep; sleep disorder; sleep phase rhythm disturbance; 
somnambulism
Ischemic heart disease 
(sMQ ischemic heart 
disease sub-sMQ other 
ischemic heart disease) 
(broad)
angina pectoris; angina unstable; arteriogram coronary abnormal; arteriosclerosis coronary artery; arteriospasm 
coronary; cardiac stress test abnormal; computerized tomogram; coronary artery abnormal; coronary 
angioplasty; coronary arterial stent insertion; coronary artery bypass; coronary artery disease; coronary 
artery dissection; coronary artery insufficiency; coronary artery restenosis; coronary artery stenosis; coronary 
endarterectomy; coronary no-reflow phenomenon; coronary ostial stenosis; coronary revascularization; 
dissecting coronary artery aneurysm; electrocardiogram signs of myocardial; electrocardiogram sT segment 
depression; electrocardiogram sT–T segment abnormal; electrocardiogram sT–T segment depression; 
electrocardiogram T-wave abnormal; electrocardiogram T-wave inversion; exercise electrocardiogram 
abnormal; exercise test abnormal; external counterpulsation; hemorrhage coronary artery; in-stent coronary 
artery restenosis; ischemic cardiomyopathy; microvascular angina; myocardial ischemia; other ischemic heart 
disease (broad) ischemia; percutaneous coronary intervention; prinzmetal angina; stress cardiomyopathy; stress 
echocardiogram abnormal; subclavian coronary steal; syndrome; subendocardial ischemia
(Continued)
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Table S1 (Continued)
PV endpoint/SMQ MedDRA PT
MI (sMQ ischemic 
heart disease sub-sMQ 
myocardial infarction) 
(broad)
acute coronary syndrome; acute myocardial infarction; blood creatine phosphokinase; MB abnormal; 
blood creatine phosphokinase; MB increased; blood creatine phosphokinase abnormal; blood creatine 
phosphokinase increased; cardiac enzymes increased; coronary artery embolism; coronary artery occlusion; 
coronary artery reocclusion; coronary artery thrombosis; coronary bypass thrombosis; electrocardiogram 
electrically inactive area; electrocardiogram Q-wave abnormal; electrocardiogram sT segment abnormal; 
electrocardiogram sT segment elevation; electrocardiogram sT−T segment elevation; infarction; Kounis 
syndrome; myocardial infarction; myocardial reperfusion injury; myocardial stunning; papillary muscle 
infarction; postprocedural myocardial infarction; postinfarction angina; scan myocardial perfusion abnormal; 
silent myocardial infarction; troponin I increased; troponin T increased; troponin increased; vascular graft 
occlusion
Palpitations extrasystoles; palpitations; supraventricular extrasystoles; ventricular extrasystoles
Pneumonia atypical mycobacterial pneumonia; bronchopneumonia; congenital pneumonia; embolic pneumonia; 
enterobacter pneumonia; lobar pneumonia; miliary pneumonia; neonatal pneumonia; pneumonia; pneumonia 
adenoviral; pneumonia anthrax; pneumonia bacterial; pneumonia blastomyces; pneumonia Bordetella; 
pneumonia Chlamydial; pneumonia Cryptococcal; pneumonia Cytomegaloviral; pneumonia escherichia; 
pneumonia fungal; pneumonia hemophilus; pneumonia helminthic; pneumonia herpes viral; pneumonia 
influenzal; pneumonia Klebsiella; pneumonia Legionella; pneumonia measles; pneumonia Moraxella; pneumonia 
mycoplasmal; pneumonia necrotizing; pneumonia parainfluenzae viral; pneumonia pneumococcal; pneumonia 
primary atypical; pneumonia respiratory syncytial viral; pneumonia salmonella; pneumonia staphylococcal; 
pneumonia streptococcal; pneumonia toxoplasmal; pneumonia Tularemia; pneumonia viral; post procedural 
pneumonia
renal failure acute prerenal failure; anuria; cardiorenal syndrome; diabetic end-stage renal disease; hepatorenal failure; 
postoperative renal failure; renal failure; renal failure acute; renal failure chronic
respiratory failure acute respiratory failure; cardiopulmonary failure; chronic respiratory failure; hypoxia; respiratory acidosis; 
respiratory failure; respiratory paralysis
restlessness agitation; psychomotor hyperactivity; restlessness
sleep disturbance abnormal dreams; insomnia; nightmare; poor quality sleep; sedation; sleep disorder; sleep phase rhythm 
disturbance; sleep talking; somnambulism; somnolence
stomatitis aphthous stomatitis; mouth ulceration; oral mucosal eruption; oropharyngeal blistering; stomatitis; stomatitis 
hemorrhagic; stomatitis necrotizing
stroke amaurosis fugax; basal ganglia hemorrhage; basilar artery occlusion; basilar artery thrombosis; brachiocephalic 
artery occlusion; brain stem hemorrhage; brain stem infarction; brain stem ischemia; brain stem stroke; brain 
stem thrombosis; carotid aneurysm rupture; carotid arterial embolus; carotid artery occlusion; carotid artery 
thrombosis; central nervous system hemorrhage; cerebellar artery occlusion; cerebellar artery thrombosis; 
cerebellar embolism; cerebellar hematoma; cerebellar hemorrhage; cerebellar infarction; cerebellar ischemia; 
cerebral arteriovenous malformation hemorrhagic; cerebral artery embolism; cerebral artery occlusion; 
cerebral artery thrombosis; cerebral hematoma; cerebral hemorrhage; cerebral hemorrhage fetal; cerebral 
hemorrhage neonatal; cerebral infarction; cerebral infarction fetal; cerebral ischemia; cerebral thrombosis; 
cerebrovascular accident; embolic cerebral infarction; embolic stroke; hemorrhage intracranial; hemorrhagic 
cerebral infarction; hemorrhagic stroke; hemorrhagic transformation stroke; intracranial hematoma; 
intracranial tumor hemorrhage; intraoperative cerebral artery occlusion; intraventricular hemorrhage; 
intraventricular hemorrhage neonatal; ischemic cerebral infarction; ischemic stroke; lacunar infarction; lateral 
medullary syndrome; pituitary hemorrhage; pituitary infarction; postprocedural stroke; precerebral artery 
occlusion; putamen hemorrhage; reversible ischemic neurological deficit; ruptured cerebral aneurysm; stroke 
in evolution; subarachnoid hemorrhage; subarachnoid hemorrhage neonatal; subdural hemorrhage neonatal; 
thalamic infarction; thalamus hemorrhage; thrombotic cerebral infarction; thrombotic stroke; transient 
ischemic attack; vertebral artery dissection; vertebral artery occlusion; vertebral artery thrombosis
supraventricular 
tachycardia
atrial tachycardia; postural orthostatic tachycardia syndrome; sinus tachycardia; supraventricular tachycardia; 
tachycardia paroxysmal
syncope loss of consciousness; presyncope; syncope
Tachycardia heart rate increased; sinus tachycardia; tachycardia
Urinary retention Bladder neck obstruction; residual urine volume increased; urinary hesitation; urinary retention; urinary 
retention postoperative; urinary tract obstruction; urine flow decreased
(Continued)
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Table S1 (Continued)
PV endpoint/SMQ MedDRA PT
Urinary tract infection adenoviral hemorrhagic; cystitis; asymptomatic bacteriuria; bacterial pyelonephritis; bacteriuria; bladder 
candidiasis; cystitis; cystitis escherichia; cystitis glandularis; cystitis gonococcal; cystitis hemorrhagic; cystitis 
interstitial; cystitis Klebsiella; cystitis noninfective; cystitis pseudomonal; cystitis radiation; cystitis ulcerative; 
cytomegalovirus urinary tract infection; emphysematous cystitis; eosinophilic cystitis; escherichia urinary 
tract infection; fungal cystitis; genitourinary tract infection; kidney infection; perinephric abscess; pyelocystitis; 
pyelonephritis; pyelonephritis acute; pyelonephritis chronic; pyelonephritis mycoplasmal; pyonephrosis; 
renal abscess; renal cyst infection; schistosomiasis bladder; streptococcal urinary tract infection; trigonitis; 
tuberculosis bladder; ureter abscess; ureteritis; urethral abscess; urethral carbuncle; urethral stricture 
post infection; urethritis; urinary bladder abscess; urinary tract abscess; urinary tract infection; urinary 
tract infection bacterial; urinary tract infection enterococcal; urinary tract infection fungal; urinary tract 
infection neonatal; urinary tract infection pseudomonal; urinary tract infection staphylococcal; urosepsis; viral 
hemorrhagic cystitis
Ventricular tachycardia/
fibrillation
Ventricular fibrillation; ventricular tachycardia
Vision blurred accommodation disorder; altered visual depth perception; diplopia; erythropsia; glare; halo vision; 
hypermetropia; loss of visual contrast sensitivity; malignant myopia; myopia; night blindness; oscillopsia; 
phosphenes; photopsia; presbyopia; refraction disorder; tunnel vision
Abbreviations: MB, creatine kinase-MB; MedDra, Medical Dictionary for regulatory activities; MI, myocardial infarction; PT, preferred term; PV, pharmacovigilance; 
sMQ, standardized MedDra queries.
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